Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - Patent Issued for Method for Treating Hypertension (USPTO 9744165) - November 18, 2017

Pharmacy News Article

 9/11/17 - Patent Issued for Method for Treating Hypertension (USPTO 9744165)

By a News Reporter-Staff News Editor at Clinical Trials Week TSH Biopharm Corporation Ltd. (Taipei, TW) has been issued patent number 9744165, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also TSH Biopharm Corporation Ltd.).

The patent's inventors are Chen, Jaw-Wen (Taipei, TW); Wang, Hsi-Chieh (Taipei, TW); Juang, Shin-Yi (Taipei, TW).

This patent was filed on April 28, 2016 and was published online on August 29, 2017.

From the background information supplied by the inventors, news correspondents obtained the following quote: "Hypertension is a public health problem that affects more than 25% of the adult population worldwide. [1,2] Hypertension has been identified as the leading risk factor for mortality and ranks as the third-leading cause of disability-adjusted life-years. [1,3] Despite the availability of numerous antihypertensive agents, the diagnosis, management, and control of hypertension are far from ideal, with control rates of 6% to 30% in different communities worldwide. [1] Nonadherence to antihypertensive treatment has been associated with lower rates of blood pressure (BP) control and higher rates of cardiovascular events. [4-6] Administration of a once-daily fixed-dose combination (FDC) therapy with >2 classes of antihypertensive agents is a strategy adopted for improving adherence and BP control. This strategy has been described in the recent guidelines, even as an initial therapeutic option. [7,8]

"NADPH oxidases have recently been shown to contribute to the pathogenesis of hypertension. See Williams et al., 2007, J. Cardiovasc Pharmacol., 50:9-16 and references therein. It has been suggested that specific inhibitors of these enzymes may have potential therapeutic use in hypertensive disease. Two of the most specific inhibitors, gp91ds-tat and apocynin, have been shown to decrease blood pressure in animal models of hypertension. Other inhibitors, including diphenylene iodonium, aminoethyl benzenesulfono fluoride, S17834, PR39, protein kinase C inhibitors, and VAS2870, have shown promise in vitro, but their in vivo specificity, pharmacokinetics, and effectiveness in hypertension remains to be determined. The currently available antihypertensive agents, angiotensinconverting enyzme inhibitors and angiotensin receptor blockers also effectively inhibit NADPH oxidase activation. Similarly, the cholesterol-lowering agents, statins, have been shown to attenuate NADPH oxidase activation.

"Dextromethorphan (DM) is a dextrorotatory morphinan and is widely used as a nonopioid cough suppressant in a variety of over-the-counter remedies. [17] It is an NMDA receptor antagonist. The exact mechanism of action of its antitussive activity, however, remains unclear. Studies using animal models of cerebral ischemia and hypoglycemic neural injuries have demonstrated that DM possesses neuroprotective activity. [18-23] DM effectively inhibited the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced production of reactive oxygen species (ROS). The neuroprotective effect of DM depended on the normal function of NADPH oxidase.[24] Recent in vitro and in vivo studies showed that DM reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice through the direct inhibition of NADPH oxidase and that it also decreases superoxide production in the aorta and carotid artery of apolipoprotein E (apoE)-deficient mice. Liu et al., 2009, Cardiovascular Research, 82:161-169. Alvarez Y et al suggest that the increased production of superoxide anion (O.sub.2.sup.-) from NADP(H) oxidase in vessels of hypertensive rats contributes to the vasoconstrictor responses and counteracts the increase of NO from iNOS and the consequent modulation of these responses. [25]

"Calcium channel blockers (CCBs) are indicated as initial therapy for hypertension. Their benefits and the possible risks have been explored in several clinical trials. [9-14] Use of high-dose CCBs has been associated with a high incidence of adverse events (AEs), such as peripheral edema and constipation. [8,11,12]

"Amlodipine is a CCB with antihypertensive properties prescribed as monotherapy. It is one of a series of dihydropyridine calcium antagonists. It has been found to be well tolerated even in high-risk patients, such as those with coronary disease, heart failure, or multiple risk factors for cardiovascular events. [12-16] Amlodipine has a generally slower onset and longer duration of action than, for example, nifedipine. (Jensen, H. et al., J. Hum. Hypertens., 42(S): 541-45, 1990). The metabolites of amlodipine apparently do not possess significant calcium channel blocking activity, while the parent drug offers a biological half-life of some 35-40 hours, prompting a once-daily dosage regimen. (Lorimer, A. R., et al., J. Hum. Hypertens., 3(3): 191-96, 1989; Glasser, S. F. et al., AJH, 2(3): 154-57, 1989). Its ability to block, calcium channels in smooth muscle produces peripheral vasodilation resulting in decreases in both systolic and diastolic blood pressure. The racemic mixture of amlodipine is presently used primarily as an antihypertensive agent, which produces peripheral vasodilation, resulting in decreases in both systolic and diastolic blood pressure when used as an antihypertensive agent. This antihypertensive effect occurs in the relative absence of significant or sustained effects on cardiac rate. However, the administration of the racemic mixture of amlodipine to a human has been found to cause adverse effects, such as edema of the extremities, peripheral edema, headache, flushing/hot flashes, fatigue, vertigo, muscle cramps and dizziness.

"There remains a need of novel effective and safe methods and pharmaceutical compositions for treating or preventing hypertension and related symptoms. Such methods and pharmaceutical compositions are described in the present application."

Supplementing the background information on this patent, NewsRx reporters also obtained the inventors' summary information for this patent: "It is now discovered that dextromethorphan not only is effective to lower blood pressure in a subject suffering from hypertension, but also acts synergistically with a calcium channel blocker to result in a major improvement in the treatment of hypertension, with no or little adverse effects.

"In one general aspect, embodiments of the present invention relate to a method of treating hypertension or a symptom associated therewith in a subject. The method comprises administering to the subject a pharmaceutical composition comprising an effective amount of dextromethorphan and a pharmaceutically acceptable carrier.

"In one general aspect, embodiments of the present invention relate to a method of treating hypertension or a symptom associated therewith in a subject. The method comprises administering to the subject an effective amount of dextromethorphan and an effective amount of a calcium channel blocker.

"In another general aspect, embodiments of the present invention relate to a pharmaceutical composition for treating hypertension or a symptom associated therewith in a subject, comprising an effective amount of dextromethorphan, an effective amount of a calcium channel blocker, and a pharmaceutically acceptable carrier.

"In a preferred embodiment, the present invention relates to a pharmaceutical composition for treating hypertension or a symptom associated therewith in a subject, which comprises an effective amount of dextromethorphan, an effective amount of amlodipine, and a pharmaceutically acceptable carrier.

"In another general aspect, embodiments of the present invention relate to a pharmaceutical composition for treating hypertension or a symptom associated therewith in a subject, comprising an effective amount of a calcium channel blocker, an effective amount of a NADPH oxidase inhibitor, and a pharmaceutically acceptable carrier.

"Other aspects of the present invention relate to methods of treating hypertension or a symptom associated therewith in a subject, comprising administering to the subject an effective amount of a calcium channel blocker, such as amlodipine, and an effective amount of a NADPH oxidase inhibitor, such as dextromethorphan.

"Other aspects, features and advantages of the invention will be apparent from the following disclosure, including the detailed description of the invention and its preferred embodiments and the appended claims."

For the URL and additional information on this patent, see: Chen, Jaw-Wen; Wang, Hsi-Chieh; Juang, Shin-Yi. Method for Treating Hypertension. U.S. Patent Number 9744165, filed April 28, 2016, and published online on August 29, 2017. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9744165.PN.&OS=PN/9744165RS=PN/9744165

Keywords for this news article include: Antihypertensive, Antitussive Agents, Pharmaceuticals, Edema, Angiology, Analgesics, Cardiology, Hemodynamics, Ion Channels, Vasodilation, Flavoproteins, NADPH Oxidase, Blood Pressure, Carrier Proteins, Membrane Proteins, Amlodipine Therapy, Drugs and Therapies, Risk and Prevention, Cardiovascular Agents.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415